🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

29 recruiting trials

for Platinum-resistant Recurrent Ovarian Cancer

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site📍 Scottsdale Mayo Clinic · Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients NCT06522828Phase 21 site📍 Chongqing Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: SSGJ-707, carboplatin, paclitaxel SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492Phase 32 sites📍 Beijing📍 Hangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1921, Doxorubicin, Paclitaxel, Topotecan Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. NCT05753826Phase 21 site📍 Fujian Fujian Cancer Hospital · Tests: Adebrelimab, Fuzuloparib APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST NCT06687070Phase 11 site📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG -2449, PLD A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors NCT06515613Phase 115 sites📍 Little Rock📍 Beverly Hills📍 Denver Context Therapeutics Inc. · Tests: CTIM-76 Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer NCT04921527Phase 31 site📍 Shanghai Chipscreen Biosciences, Ltd. · Tests: chiauranib, Placebo, Paclitaxel A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer NCT06710288Phase 22 sites📍 El Segundo📍 Newport Beach ImmunityBio, Inc. · Tests: Gemcitabine, N-803, M-CENK Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484Phase 12 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2 Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. NCT06660511EARLY Phase 11 site📍 Changsha Second Xiangya Hospital of Central South University · Tests: Disitamab Vedotin in Combination With Anlotinib Hydrochloride DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer NCT06964009Phase 13 sites📍 Boston📍 Boston📍 Boston Elizabeth Stover, MD, PhD · Tests: DT2216, Paclitaxel HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069Phase 31 site📍 Beijing Hansoh BioMedical R&D Company · Tests: HS-20089, Paclitaxel, Doxorubicin, Topotecan Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors NCT07444814Phase 112 sites📍 Little Rock📍 Los Angeles📍 Peoria Whitehawk Therapeutics, Inc. · Tests: HWK-007 A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. NCT07664735Phase 15 sites📍 San Francisco📍 Atlanta📍 Detroit Outpace Bio, Inc. · Tests: OPB-201 Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer NCT05983276Phase 21 site📍 Maywood Loyola University · Tests: Decitabine, Carboplatin, Paclitaxel, Selinexor Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells NCT06305299Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer NCT06014528Phase 21 site📍 Beijing InxMed (Shanghai) Co., Ltd. · Tests: IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer NCT04518501Phase 1, Phase 21 site📍 Zhejiang Xing Xie · Tests: Arsenic trioxide Tablet +Fuzuloparib Capsules A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. NCT06434610Phase 217 sites📍 Beijing📍 Bengbu📍 Changsha Shanghai Jiaolian Drug Research and Development Co., Ltd · Tests: B013, Paclitaxel, Placebo Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors NCT06646627Phase 11 site📍 Palo Alto Stanford University · Tests: B7-H3CART ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer NCT04055649Phase 22 sites📍 Detroit📍 Flint Ira Winer · Tests: Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites📍 Buffalo📍 Houston Roswell Park Cancer Institute · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire A… Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer NCT04633239Phase 127 sites📍 Phoenix📍 Irvine📍 Los Angeles National Cancer Institute (NCI) · Tests: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Olaparib Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer NCT05950464Phase 114 sites📍 Augusta📍 Chicago📍 Iowa City National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance I… A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) NCT06994195Phase 31 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma NCT07540403n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) NCT05281471Phase 333 sites📍 Mobile📍 Tucson📍 Duarte Genelux Corporation · Tests: olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Ph… Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study NCT07495384NA1 site📍 Changchun The First Hospital of Jilin University · Tests: CapsuleX First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites📍 Aurora📍 Sarasota📍 Detroit Accent Therapeutics · Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy